Search

Your search keyword '"Hichri Y"' showing total 9 results
Start Over Author "Hichri Y"
9 results on '"Hichri Y"'

6. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

Author

Dhedin, N, Huynh, A, Maury, S, Tabrizi, R, Beldjord, K, Asnafi, V, Thomas, X, Chevallier, P, Nguyen, S, Coiteux, V, Bourhis, J H, Hichri, Y, Escoffre-Barbe, M, Reman, O, Graux, C, Chalandon, Y, Blaise, D, Schanz, U, Lhéritier, V, Dombret, Hervé, Ifrah, N, University of Zurich, and Ifrah, N

Subjects
1307 Cell Biology, 2403 Immunology, 1303 Biochemistry, 10032 Clinic for Oncology and Hematology, 2720 Hematology, 610 Medicine & health
Published
2015

8. [Transfer of allogeneic stem cell transplant recipients to the intensive care unit: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)].

Author

Moreau AS, Bourhis JH, Contentin N, Couturier MA, Delage J, Dumesnil C, Gandemer V, Hichri Y, Jost E, Platon L, Jourdain M, Pène F, and Yakoub-Agha I

Subjects
Critical Care statistics & numerical data, Family psychology, France, Hospital Mortality, Humans, Patient Transfer ethics, Patient Transfer methods, Patient Transfer organization & administration, Prognosis, Societies, Medical, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation psychology, Intensive Care Units, Patient Transfer standards, Physician's Role, Records
Abstract

Transferring a patient undergoing an allogeneic stem cell transplantation to the intensive care unit (ICU) is always a challenging situation on a medical and psychological point of view for the patient and his relatives as well as for the medical staff. Despite the progress in hematology and intensive care during the last decade, the prognosis of these patients admitted to the ICU remains poor and mortality is around 50 %. The harmonization working party of the SFGM-TC assembled hematologists and intensive care specialist in order to improve conditions and modalities of the transfer of a patient after allogeneic stem cell transplantation to the ICU. We propose a structured medical form comprising all essential information necessary for optimal medical care on ICU., (Copyright © 2016. Published by Elsevier Masson SAS.)

Published
2016
Full Text
View/download PDF

9. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Author

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, and Ifrah N

Subjects
Adolescent, Adult, Disease-Free Survival, Female, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm, Residual, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Remission Induction, Transplantation, Homologous, Young Adult, Clinical Trials as Topic, Outcome Assessment, Health Care methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Stem Cell Transplantation methods
Abstract

Because a pediatric-inspired Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) protocol yielded a markedly improved outcome in adults with Philadelphia chromosome-negative ALL, we aimed to reassess the role of allogeneic stem cell transplantation (SCT) in patients treated in the GRAALL-2003 and GRAALL-2005 trials. In all, 522 patients age 15 to 55 years old and presenting with at least 1 conventional high-risk factor were candidates for SCT in first complete remission. Among these, 282 (54%) received a transplant in first complete remission. At 3 years, posttransplant cumulative incidences of relapse, nonrelapse mortality, and relapse-free survival (RFS) were estimated at 19.5%, 15.5%, and 64.7%, respectively. Time-dependent analysis did not reveal a significant difference in RFS between SCT and no-SCT cohorts. However, SCT was associated with longer RFS in patients with postinduction minimal residual disease (MRD) ≥10(-3) (hazard ratio, 0.40) but not in good MRD responders. In B-cell precursor ALL, SCT also benefitted patients with focal IKZF1 gene deletion (hazard ratio, 0.42). This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy. Trial GRAALL-2003 was registered at www.clinicaltrials.gov as #NCT00222027; GRAALL-2005 was registered as #NCT00327678., (© 2015 by The American Society of Hematology.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results